106 studies found for:    INCB018424 | Exclude Unknown
Show Display Options
Rank Status Study
21 Active, not recruiting Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
Condition: Myeloproliferative Diseases
Interventions: Drug: Ruxolitinib;   Drug: Lenalidomide;   Drug: Prednisone
22 Not yet recruiting A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Condition: B-cell Acute Lymphoblastic Leukemia
Interventions: Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
23 Completed Phase l/II Study of Ruxolitinib for Acute Leukemia
Condition: Leukemia
Intervention: Drug: Ruxolitinib
24 Recruiting Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post Polycythemia Vera Myelofibrosis;   Post Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
25 Active, not recruiting Study of Ruxolitinib in Colorectal Cancer Patients
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Ruxolitinib;   Drug: Regorafenib;   Drug: Placebo
26 Completed
Has Results
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib
27 Completed Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis
Condition: Plaque Psoriasis
Intervention: Drug: INCB018424
28 Recruiting Evaluation of Ruxolitinib And Azacytidine Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm
Condition: Leukemia
Interventions: Drug: Ruxolitinib (RUX);   Drug: Azacitidine (AZA);   Behavioral: Questionnaires
29 Terminated Ruxolitinib in Patients With Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Ruxolitinib
30 Withdrawn Ruxolitinib in Combination With Autotransplant
Conditions: Myelofibrosis;   MF
Interventions: Drug: RUXOLITINIB / INC 424;   Drug: Filgrastim;   Drug: Busulfan
31 Recruiting Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
32 Active, not recruiting Topical Ruxolitinib for the Treatment of Vitiligo
Condition: Vitiligo
Intervention: Drug: Ruxolitinib 1.5% Phosphate Cream
33 Recruiting TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Conditions: Myelofibrosis;   Polycythemia Vera
Interventions: Drug: TGR-1202;   Drug: ruxolitinib
34 Recruiting Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF
Conditions: Primary Myelofibrosis;   Secondary Myelofibrosis;   PMF;   SMF;   Post-PV MF;   Post-ET MF
Intervention: Drug: INCB018424/CC-4047
35 Recruiting A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Condition: Myelomonocytic Leukemia
Intervention: Drug: Ruxolitinib
36 Active, not recruiting Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Ruxolitinib;   Drug: Placebo;   Drug: Pemetrexed;   Drug: Cisplatin
37 Recruiting Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Conditions: Metastatic Breast Cancer;   Breast Carcinoma;   HER-2 Positive Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Trastuzumab
38 Active, not recruiting Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Conditions: Recurrent Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel
39 Active, not recruiting Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.
Condition: Polycythemia Vera
Interventions: Drug: Best Available Therapy;   Drug: ruxolitinib
40 Recruiting Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Conditions: Chronic Phase Chronic Myeloid Leukemia;   Accelerated Phase Chronic Myeloid Leukemia;   Blastic Phase Chronic Myeloid Leukemia;   Philadelphia Positive Acute Lymphoblastic Leukemia;   Resistant to Tyrosine Kinase Inhibitor Therapy
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years